clinical assessment diagnosis and management of cocaine and other stimulatnt use disordr

Reading File

Finding Sources

Searching PubMed

"cocaine use disorder" OR "stimulant use disorder" treatment management

Searching the Web

cocaine stimulant use disorder clinical assessment diagnosis management 2024 2025 guidelines

Reading File

Finding Sources

Reading Web Page

https://www.suguidelinesnys.org/guideline/stimulant-use

Reading File

I now have comprehensive content from Kaplan & Sadock's Comprehensive Textbook of Psychiatry, Goldman-Cecil Medicine, Rosen's Emergency Medicine, and Kaplan & Sadock's Synopsis of Psychiatry, plus current guidelines (NYSDOH/ASAM 2023, SAMHSA). Here is the full clinical response:

Cocaine and Other Stimulant Use Disorder: Clinical Assessment, Diagnosis, and Management

1. Overview and Epidemiology

Stimulants covered under this category include cocaine (powder and crack), amphetamines, methamphetamine, MDMA, and synthetic cathinones ("bath salts"). DSM-5-TR unified cocaine-related and amphetamine-related disorders into a single Stimulant Use Disorder (StUD) framework, recognizing their overlapping mechanisms, clinical presentations, and treatment approaches.

Stimulant use disorders are among the most heritable psychiatric conditions. Twin studies place the heritability of cocaine use disorder at 60-80% and amphetamine-type stimulant use disorder at approximately 68%. Heritable traits such as novelty-seeking, impulsivity, and stress reactivity act as intermediate risk factors.

Kaplan & Sadock's Comprehensive Textbook of Psychiatry

2. Pharmacology and Mechanism

Agent	Primary Mechanism	Duration of Action
Cocaine	Blocks dopamine transporter (DAT), norepinephrine transporter, serotonin transporter; also blocks fast Na+ channels	15-60 min (smoked: 10-15 min)
Amphetamines	Stimulate presynaptic dopamine release; reverse DAT	4-8 hours
Methamphetamine	Same as amphetamines, more potent; also inhibits MAO	Up to 12 hours
MDMA	Promotes serotonin, dopamine, norepinephrine release	3-6 hours

The mesolimbic dopamine system (nucleus accumbens, ventral tegmental area) is the substrate for the powerful reinforcing effects. Susceptible individuals can develop dependence after only a few exposures.

Goldman-Cecil Medicine; Katzung's Basic and Clinical Pharmacology

3. Clinical Assessment

3a. Screening

Annual substance use screening is recommended for all adult patients. A positive screen for stimulant use or history of StUD or overdose warrants a full risk assessment. Key validated tools include:

CAGE-AID (adapted for drugs)
DAST-10 (Drug Abuse Screening Test)
AUDIT-C (includes polysubstance context)
Urine drug screen (cocaine metabolites - benzoylecgonine - detectable 2-4 days after single use, up to 10-12 days in heavy users)

3b. Signs of Intoxication

Sympathomimetic toxidrome:

Mydriasis (dilated pupils)
Tachycardia, hypertension
Diaphoresis or chills
Psychomotor agitation
Elevated temperature
Nausea/vomiting
Euphoria, grandiosity, increased energy, decreased appetite
At higher doses: anxiety, irritability, paranoia, psychosis

Serious complications of acute intoxication:

Seizures (grand mal - occur with intoxication, not withdrawal)
Myocardial infarction (vasospasm + accelerated atherosclerosis)
Intracranial hemorrhage
Ventricular tachyarrhythmias, Brugada-type pattern
Hyperthermia, rhabdomyolysis
Agitated delirium ("excited delirium")

Smoking cocaine produces the fastest onset (6-10 seconds) and shortest duration. Methamphetamine produces paranoia lasting days to weeks, versus hours for cocaine.

Kaplan and Sadock's Synopsis of Psychiatry (Table 4-30); Rosen's Emergency Medicine; Goldman-Cecil Medicine

3c. Cocaine Washout Syndrome

After a cocaine binge, the user may enter a washout state: profoundly sedated but arousable and oriented, with normal or mildly bradycardic vital signs. This must be distinguished from opioid overdose and medical causes of depressed consciousness.

Rosen's Emergency Medicine

3d. Withdrawal Features

Stimulant withdrawal is not medically life-threatening (unlike alcohol or benzodiazepine withdrawal). Features include:

Profound fatigue, hypersomnia
Increased appetite ("carbohydrate craving")
Dysphoria, anhedonia, depression (can be serious)
Powerful craving for the drug
"Suicide Sundays" in MDMA users (post-serotonin depletion low mood)

Withdrawal symptoms peak at 1-3 days and generally resolve over 1-2 weeks. They may persist as prolonged anhedonia in heavy users.

Goldman-Cecil Medicine; Kaplan & Sadock's Comprehensive Textbook

4. Diagnosis

DSM-5-TR: Stimulant Use Disorder

A maladaptive pattern of stimulant use causing clinically significant impairment or distress, with at least 2 of 11 criteria within a 12-month period:

Using more than intended or for longer than intended
Persistent desire to cut down or inability to control use
Significant time spent obtaining, using, or recovering from stimulant effects
Craving or strong desire/urge to use
Recurrent use failing to fulfill major role obligations (work, school, home)
Continued use despite persistent social/interpersonal problems caused by use
Important activities given up or reduced
Recurrent use in physically hazardous situations
Continued use despite knowing it is causing physical or psychological harm
Tolerance (need for increased amounts; diminished effect with same amount)
Withdrawal (characteristic syndrome or use to relieve/avoid withdrawal)

Severity grading:

Mild: 2-3 criteria
Moderate: 4-5 criteria
Severe: 6 or more criteria

The specific substance (amphetamine-type, cocaine, or other/unspecified) is noted.

Kaplan & Sadock's Comprehensive Textbook of Psychiatry

DSM-5 Stimulant Intoxication

Recent use + at least 2 of:

Tachycardia/bradycardia, hypo/hypertension
Mydriasis
Sweating or chills
Nausea/vomiting
Psychomotor agitation/retardation
Weight loss
Muscular weakness, respiratory depression
Chest pain, arrhythmias
Confusion, seizures, dyskinesias, dystonias, or coma

DSM-5 Stimulant Withdrawal

Cessation after prolonged heavy use + dysphoric mood + 2 or more of: fatigue, vivid/unpleasant dreams, insomnia or hypersomnia, increased appetite, psychomotor agitation or retardation.

Stimulant-Induced Psychiatric Disorders (rule out independent disorder)

Disorder	Notes
Stimulant-induced psychotic disorder	Nonbizarre delusions, paranoia, tactile hallucinations ("cocaine bugs") - usually resolves with abstinence
Stimulant-induced bipolar/depressive disorder	Binge-washout cycles can mimic bipolar disorder
Stimulant-induced anxiety disorder
Stimulant-induced OCD
Stimulant-induced sleep disorder

Key rule: Symptoms persisting beyond 1 month of abstinence or predating stimulant use suggest an independent (primary) psychiatric disorder. Careful timeline history is essential.

Kaplan & Sadock's Comprehensive Textbook of Psychiatry

5. Differential Diagnosis

Mania or hypomania - binge cycles can closely mimic bipolar disorder
Schizophrenia/brief psychotic disorder - vs stimulant-induced psychosis
PCP intoxication - shares sympathomimetic + psychotic features with cocaine
Hyperthyroidism, pheochromocytoma - tachycardia, diaphoresis, anxiety
Other stimulant intoxication (MDMA, bath salts, ephedrine)
Sedative-hypnotic withdrawal (agitation, diaphoresis, seizures - but has its own signs)

6. Complications by Route and Organ System

System	Complications
Cardiovascular	MI, vasospasm, cardiomyopathy, arrhythmias, aortic dissection, Brugada pattern
CNS	Stroke (ischemic and hemorrhagic), seizures, cognitive impairment
Pulmonary	"Crack lung," pneumothorax, pneumomediastinum
ENT/nasal	Sinusitis, septal perforation, nasopalatine necrosis
Infectious	HIV, hepatitis B/C (IV use), endocarditis, abscesses
Psychiatric	Psychosis, depression, anxiety, bipolar-like cycles
Metabolic	Hyperthermia, rhabdomyolysis, hypo/hyperkalemia

Cocaine's secondary harm extends to cellulitis from injection, trauma, and STIs from risky drug-seeking behavior.

Rosen's Emergency Medicine; Goldman-Cecil Medicine

7. Management

7a. Acute Intoxication (Emergency Management)

Supportive care is the mainstay - no specific antidote
Agitation/paranoia: Benzodiazepines (first-line); antipsychotics (second-line - note QT prolongation risk; avoid haloperidol if Brugada pattern suspected)
Hypertension/chest pain: Benzodiazepines, nitrates, calcium channel blockers. Avoid beta-blockers (risk of unopposed alpha-adrenergic vasoconstriction worsening ischemia)
Hyperthermia: Active cooling, benzodiazepines
Seizures: Benzodiazepines; exclude hypoglycemia and structural causes
Arrhythmias: Sodium bicarbonate for wide-complex tachycardia from Na+ channel blockade; treat hypokalemia
Most patients recover spontaneously within hours

7b. Withdrawal

Generally outpatient management - does not require hospitalization
Supportive care: sleep, nutrition, hydration
Short-term benzodiazepines for severe agitation or anxiety
Monitor for serious depression and suicidal ideation (especially methamphetamine)

7c. Treatment Setting

Stimulant use disorder treatment is typically initiated outpatient because withdrawal is not medically dangerous. Inpatient or residential setting is indicated for:

Persistent psychosis or suicidality
Medical complications (MI, stroke, infection)
Co-occurring disorders requiring intensive treatment
Multiple drug dependencies (alcohol, opioid co-dependence requiring monitored detox)
Failure at lower levels of care / need to remove from drug-using environment

7d. Psychosocial Treatments (Cornerstone of Care)

No FDA-approved medication exists for cocaine or amphetamine use disorder. Behavioral therapies are the primary, evidence-based treatment.

1. Contingency Management (CM) - strongest evidence:

Uses operant conditioning: positive reinforcement (vouchers, cash prizes) for drug-free urine screens and treatment attendance
Systematic reviews consistently show CM is more effective than CBT, 12-step, and other behavioral strategies for stimulant use disorders
A "fishbowl" intermittent reinforcement schedule (variable ratio) maximizes engagement
Practical challenge: implementing real-world incentive structures

2. Cognitive Behavioral Therapy (CBT):

Identifies and modifies thoughts, beliefs, and behaviors that trigger or maintain use
Teaches coping skills for cravings, high-risk situations, relapse prevention
Well-studied for cocaine use disorder

3. 12-Step Facilitation (TSF) / Narcotics Anonymous (NA):

Connects patients to mutual-help groups and peer support
Community Reinforcement Approach (CRA) integrates 12-step principles with CBT
Self-help involvement and sponsorship are among the most consistently identified positive prognostic factors

4. Matrix Model:

Structured intensive outpatient program combining CBT, family therapy, 12-step participation, and drug testing - widely used for methamphetamine
NYSDOH/ASAM 2023 Guideline; Kaplan & Sadock's Comprehensive Textbook of Psychiatry

7e. Pharmacotherapy

No FDA-approved medications for StUD. Evidence-based options by context:

Agent	Evidence/Notes
Bupropion XR 450 mg + injectable naltrexone 380 mg q3 weeks	Best evidence for methamphetamine use disorder; ~11% absolute improvement in abstinence at 12 weeks (Trivedi et al. 2021, NEJM)
Mirtazapine 30 mg daily	Benefit shown for methamphetamine use disorder
Modafinil	Mixed results for cocaine; may reduce craving and withdrawal fatigue in some trials
Topiramate	Some RCT evidence for cocaine use disorder; weight loss side effect may be limiting
Disulfiram	Modest evidence for cocaine; possibly deters use by adverse catecholamine interaction
N-acetylcysteine	Modulates glutamate; some evidence for cue-induced craving reduction
Aripiprazole	A 2025 systematic review found it not effective for abstinence in alcohol and stimulant use disorders without psychiatric comorbidities [PMID: 40623320]

For co-occurring ADHD and cocaine use disorder, careful use of extended-release stimulants (e.g., mixed amphetamine salts XR, lisdexamfetamine) under close monitoring has been explored - controversial but has case-report and trial support.

Goldman-Cecil Medicine; Kaplan & Sadock's Comprehensive Textbook; NYSDOH 2025 Guideline

7f. Harm Reduction

Naloxone provision (fentanyl is now commonly adulterating cocaine supplies)
Fentanyl test strip education
Safer use supplies (clean needles, pipes)
HIV and hepatitis C screening and treatment
STI screening
Safe sex counseling

8. Co-occurring Disorders (Dual Diagnosis)

Stimulant use disorders carry a high burden of psychiatric comorbidity:

Depression (very common post-cessation; anhedonia is the strongest predictor of poor prognosis)
ADHD (shared dopaminergic vulnerability; can predate and drive stimulant use)
PTSD (associated with more persistent impairment even if not predicting more cocaine use in treatment)
Bipolar disorder (binge-withdrawal cycles mimic BD; careful timeline essential)
Antisocial personality disorder

Manage co-occurring disorders independently. Persistent psychotic or severe depressive symptoms after 1 month of abstinence should prompt independent psychiatric diagnosis and treatment.

9. Prognosis

Worse Prognosis	Better Prognosis
Higher baseline use / injection use	Employment
Cognitive dysfunction, impulsivity	Greater social support
High cortisol levels	Self-help involvement, sponsorship
Anhedonia	Higher self-efficacy
Polysubstance use, tobacco use disorder	Involvement in treatment
Lower education level	Extended residential treatment (cocaine)

Severity of use disorder (baseline) is the most consistent predictor of outcome. Recent fMRI-based studies show that patterns of brain functional connectivity can predict treatment response.

Kaplan & Sadock's Comprehensive Textbook of Psychiatry

Recent Evidence Updates (2024-2026)

Contingency management remains confirmed as the strongest behavioral intervention across a 2025 systematic review [PMID: 39545650]
Aripiprazole is not effective for stimulant use disorder without psychiatric comorbidities (2025 systematic review) [PMID: 40623320]
Crack cocaine treatment review (2026) comparing multiple interventions reinforces behavioral approaches as superior to pharmacotherapy alone [PMID: 41871216]
The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2023/2024) is the current North American gold standard - published in Journal of Addictive Medicine (2024; 18[1S]:1-56)

Key Clinical Pearls:

No FDA-approved medication for cocaine/amphetamine use disorder - behavioral therapy (especially contingency management) is the proven cornerstone
Stimulant withdrawal is not medically dangerous - no need for hospital detox in most cases; risk is psychological (depression, suicidality)
Avoid beta-blockers in cocaine-associated chest pain or hypertension - use benzodiazepines and CCBs
Symptoms persisting >1 month of abstinence = independent psychiatric disorder, not stimulant-induced
Always screen cocaine users for fentanyl co-exposure given current supply contamination
Bupropion XR + naltrexone is the only pharmacotherapy combination with robust RCT evidence (for methamphetamine, not cocaine)

This is a shared conversation. Sign in to Orris to start your own chat.